NEW BRUNSWICK, N.J., Oct. 28, 2016 /PRNewswire/ -- Susan Lee Lindquist, Ph.D., member of the Johnson & Johnson (NYSE: JNJ) board of directors and world-renowned biomedical innovator, today lost her battle with cancer.
An insightful leader with an incomparable perspective on the intersection of academic and medical research, Dr. Lindquist served as an elected member of the Johnson & Johnson board of directors since 2004, chairing its Science, Technology & Sustainability Committee and sitting on its Regulatory, Compliance & Government Affairs Committee.
"Dr. Lindquist's impact in the field of biomedical innovation, as well as her entrepreneurial spirit, courageous leadership and commitment to teaching, is an inspiration for all of us and for generations to come," said Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson. "She has made invaluable contributions to Johnson & Johnson, consistently challenging us to deliver more innovation, enhance our commitment to scientific excellence, and remain focused on meeting the needs of patients worldwide."
Dr. Lindquist was a widely respected researcher with a global reputation as a pioneer in biomedical innovation. During her nearly 40-year career, she not only made numerous, instrumental contributions to the study of protein folding, but also was a committed teacher and mentor. As a biomedical entrepreneur, she co-founded FoldRx Pharmaceuticals and founded Yumanity Therapeutics and REVOLUTION Medicines. She received many awards and honors recognizing her groundbreaking work.
Dr. Lindquist earned an undergraduate degree in microbiology from the University of Illinois at Urbana-Champaign and a Ph.D. in biology from Harvard University.
"On behalf of the board of directors and the employees of Johnson & Johnson, we extend our deepest sympathies to Dr. Lindquist's family and friends, and the many colleagues and patients whose lives she touched. She will be missed," said Gorsky.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-mourns-the-loss-of-susan-lindquist-biomedical-research-pioneer-and-member-of-the-johnson--johnson-board-of-directors-300353677.html
SOURCE Johnson & Johnson